Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats

References

• Scher JU. B-cell therapies for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2012;70:200–203
   PubMedGoogle Scholar
• Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51:v3–11
   Web of Science ®Google Scholar
• Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol 2013;173:8–17
   PubMed Web of Science ®Google Scholar
• Blüml S, McKeever K, Ettinger R, et al. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013;15:S4 . doi: 10.1186/ar3906
   PubMed Web of Science ®Google Scholar
• Doorenspleet ME, Klarenbeek PL, de Hair MJ, et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann Rheum Dis 2013. [Epub ahead of print]. doi: 10.1136/annrheumdis-2012-202861
   Google Scholar
• Schmidt EM, Davies M, Mistry P, et al. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum 2013;65:2262–2273
   PubMedGoogle Scholar
• Azizi G, Jadidi-Niaragh F, Mirshafiey A. Th17 cells in immunopathogenesis and treatment of rheumatoid arthritis. Int J Rheum Dis 2013;16:243–253
   PubMed Web of Science ®Google Scholar
• Dou C, Yan Y, Dong S. Role of cadherin-11 in synovial joint formation and rheumatoid arthritis pathology. Mod Rheumatol 2013;23:1037--1044
   Google Scholar
• Tanaka S. Regulation of bone destruction in rheumatoid arthritis through RANKL- RANK pathways. World J Orthop 2013;4:1–6
   PubMedGoogle Scholar
• Ho TY, Santora K, Chen JC, et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Bone 2011;48:1346–1353
   PubMed Web of Science ®Google Scholar
• Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2013;6:35–43
   PubMedGoogle Scholar
• Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phyto-medicine-ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009;16:2924–2942
   PubMed Web of Science ®Google Scholar
• Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets. CNS Neurosci Ther 2011;17:761–768
   PubMed Web of Science ®Google Scholar
• Jung SH, Woo MS, Kim SY, et al. Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathways in human astroglioma cells. Int J Cancer 2006;118:490–497
   PubMed Web of Science ®Google Scholar
• Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation – the key step of inflammation. Biochem Pharmacol 2011;82:278–286
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Yu SC, et al. Therapeutic effects and mechanisms of total flavonoids of Turpinia Arguta seen on adjuvant arthritis in rats. J Ethnopharmacol 2008;116:167–172
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang W, Shen W, Wang K. Effects of the acid polysaccharide fraction isolated from a cultivated Cordyceps sinensis on macrophages in vitro. Cell Immunol 2010;262:69–74
   PubMed Web of Science ®Google Scholar
• Bossaller L, Rothe A. Monoclonal antibody treatments for rheumatoid arthritis. Expert Opin Biol Ther 2013;13:1257–1272
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–173
   PubMed Web of Science ®Google Scholar
• Davignon JL, Hayder M, Baron M, et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013;52:590–598
   PubMed Web of Science ®Google Scholar
• Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115–124
   PubMed Web of Science ®Google Scholar
• St Clair EW, Wilkinson WE, Lang T, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996;184:1173–1178
   PubMed Web of Science ®Google Scholar
• Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. Curr Pharm Des 2005;11:569–580
   PubMed Web of Science ®Google Scholar
• Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115:118–128
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009;11:249--262
   PubMed Web of Science ®Google Scholar
• Chang SK, Gu Z, Brenner MB. Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11. Immunol Rev 2010;233:256–266
   PubMed Web of Science ®Google Scholar
• Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233–255
   PubMed Web of Science ®Google Scholar
• Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233–255
   PubMed Web of Science ®Google Scholar
• van den Berg WB. Cytokines and joint erosion in arthritis. Nat Clin Pract Rheumatol 2008;4:58–59
   PubMedGoogle Scholar
• Liu C, Zhang Y, Kong X, et al. Triptolide prevents bone destruction in the collagen-induced arthritis model of rheumatoid arthritis by targeting RANKL/RANK/OPG signal pathway. Evid Based Complement Alternat Med 2013;2013:626038 (1--12)
   Web of Science ®Google Scholar